



University of Dundee

Treating age-related multimorbidity

Ermogenous, Christos; Green, Charlotte; Jackson, Thomas; Ferguson, Michael; Lord, Janet M.

Published in:
Drug Discovery Today

DOI:
[10.1016/j.drudis.2020.06.016](https://doi.org/10.1016/j.drudis.2020.06.016)

Publication date:
2020

Licence:
CC BY-NC-ND

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):
Ermogenous, C., Green, C., Jackson, T., Ferguson, M., & Lord, J. M. (2020). Treating age-related multimorbidity: the drug discovery challenge. *Drug Discovery Today*, 25(8), 1403-1415.
<https://doi.org/10.1016/j.drudis.2020.06.016>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



Teaser Advanced age is the major risk factor for multimorbidity. Current clinical practice treats the individual age-related diseases, resulting in polypharmacy. Thus, targeting the biological processes that drive ageing could prevent both multimorbidity and polypharmacy.



Treating age-related multimorbidity: the drug discovery challenge

Christos Ermogenous¹, Charlotte Green², Thomas Jackson¹, Michael Ferguson² and Janet M. Lord^{1,3}

¹ MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK

² Drug Discovery Unit, University of Dundee, Dundee, UK

³ NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK

Patients with multimorbidities have shorter life expectancy and their clinical management is more complex and expensive for healthcare systems currently focused on treating single diseases. Given that age is the major risk factor for multimorbidity, the challenge of treating these patients will only increase in coming years. Here, we review the case for targeting the core processes that drive the ageing phenotype as a novel pharmaceutical approach to multimorbidity. There is growing evidence that targeting ageing mechanisms can reduce or delay age-related diseases in animal models, and the first reports of clinical trials are now appearing. Although these trials currently focus on repurposed drugs, we propose several novel targets that would more specifically target ageing processes and thereby reduce multimorbidity and polypharmacy in future generations.

Introduction

Over the past 200 years, advances in public health and medical interventions have led to a dramatic increase in life expectancy, with current predictions suggesting that the total population of people aged over 60 years will double to approximately 2.1 billion by 2050 [1]. However, healthy life expectancy has not improved at the same pace, and so we are living longer but not healthier. For example, a global increase in life expectancy of 5 years between 2000 and 2015 was associated with only a 4.6-year improvement in healthspan [2]. In the UK, male life expectancy increased by 4.2 years between 1990 and 2010, but healthy life expectancy lagged behind, with a 2.7-year increase (for females, the equivalent data were 1.9 years and 1.1 years) [3]. As a result, an average of 16–20% of later life is spent in ill-health [4], with many individuals having age-related chronic diseases, such as arthritis, cancer, type 2 diabetes mellitus (T2DM), and cardiovascular and neurodegenerative disorders.

Corresponding author: Lord, J.M. (j.m.lord@bham.ac.uk)

Janet Lord is the director of the Institute of Inflammation and Ageing and the MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research at Birmingham University, UK. Her primary research focus is on the effect of ageing upon immune function and how this limits the ability of older adults to resolve inflammation and predisposes them to chronic inflammatory disease, such as rheumatoid arthritis. In 2013, she was awarded the Lord Cohen of Birkenhead medal for her outstanding research in human ageing by the British Society for Research in to Ageing. She was elected a Fellow of the Academy of Medical Sciences in 2015.



Michael Ferguson is Regius Professor of Life Sciences at the University of Dundee, UK. He is a biochemist known for the discovery and characterisation of glycosylphosphatidylinositol (GPI) protein membrane anchors. He is interested in translational research and, together with colleagues, established the Drug Discovery Unit at Dundee in 2006. He also codirects a Proteomics Facility, which supports many research projects. Mike is currently also Deputy Chair of the Board of Governors of the Wellcome Trust and on the Board of Directors of the Medicines for Malaria Venture.



Charlotte Green received her BSc (pharmacology) and PhD from the University of Dundee and has 10 years' experience in metabolic research. She has held a Marie Curie IEF and an Oxford-Novo Nordisk Fellowship. In 2018, she joined the Dundee Drug Discovery Unit as a scientific liaison manager. She also acts as a scientific liaison for the UK Spine Knowledge Exchange network, which focuses on developing new therapeutics for diseases linked with ageing.



Crucially, older adults rarely experience just one of these conditions, and multimorbidity has become the norm in old age [5]. Multimorbidity, which is defined as the coexistence of two or more chronic conditions, is highly prevalent in high-income countries and is on the rise in low- and middle-income countries [5]. Multimorbidity affects at least 50 million people in the European Union [6], whereas 80% of Medicare users in the USA have at least two chronic conditions [7]. Although not limited to older adults, multimorbidity increases substantially with age, and is the main risk factor resulting in shorter life expectancy, worsening functional capacity, poorer quality of life, longer hospital stays, and increased healthcare costs for ageing populations around the world [8,9]. A cross-sectional study of 1.7 million people in Scotland found that 30.4% of people aged between 45 and 84 years, 64.9% of people aged between 65 and 84 years, and 81.5% of people aged 85 years or above had at least two chronic diseases [10]. Another notable statistic from this study is that multimorbidity onset can occur 10–15 years earlier in individuals living in more socially deprived areas [10]. Furthermore, every additional chronic disease in over 65 year olds shortens life expectancy by on average 1.8 years [7]. There is now mounting evidence that treatments effective in the single-disease context are far less so in the context of multimorbidity, and that polypharmacy leaves patients at serious risk of adverse effects [8,11]. The current challenge to overcoming the issue of multimorbidity is that medical practice, public health strategies, and drug discovery are still focused on treating these diseases individually, even though this no longer reflects the clinical reality for older patients and might even be harmful because of polypharmacy [11]. Thus, there is an urgent need for a novel approach to age-related multimorbidity, and we suggest that this requires a drug development and testing para-

digim that focuses on the core processes driving multimorbidity rather than on its individual disease components. We suggest that it is vital that we move away from the one drug/one disease model for therapeutic interventions and drug discovery in multimorbidity towards a more holistic approach that brings its underlying causes into greater consideration. To achieve this, we need to better understand how multimorbidity develops, the specifics of different disease clusters in multimorbid patients, and the generic mechanisms driving each cluster.

Disease clustering in multimorbidity

Cross-sectional studies have begun to characterise patterns of associative multimorbidity, whereby specific pairings or clusters of diseases develop in individuals at a higher rate than expected from pure chance alone, in an attempt to provide useful evidence for better clinical management of patients with multimorbidities and to identify targetable pathways driving the different clusters [12]. Such studies have been varied in their choice of sample size, age setting, indices of multimorbidity, and statistical methodology, leading to inconsistent results that are difficult to compare between studies. Despite this variability, there does appear to be a growing consensus from multiple studies across different populations, as reviewed by Prados-Torres *et al.* [12], that multimorbidity patterns generally fall into three main clusters: cardiometabolic, neuropsychiatric, and musculoskeletal (Fig. 1). A cardiometabolic cluster, which was identified in ten of the 14 studies reviewed, most commonly involved at least two diseases, such as diabetes, hypertension, various types of heart disease (e.g., coronary heart disease or congestive heart failure), hyperlipidaemia, and obesity. A neuropsychiatric cluster was again identified in ten of the 14 cross-sectional studies reviewed and, in this instance, included at




FIGURE 1 Disease clustering in multimorbidity. Cross-sectional studies recently identified patterns of associative multimorbidity, whereby specific pairings or clusters of disease develop in individuals at a higher rate than expected from pure chance alone. CAPITALS, major component; lower case, minor component. Abbreviations: CHD, chronic heart disease; CHR, chronic heart failure; COPD, chronic obstructive pulmonary disease; GORD, gastro-oesophageal reflux disease

least one mental health condition. Of these, anxiety, depression, and chronic pain were the most frequent and were associated with a wide range of comorbidities, including, but not limited to, other neurological diseases (e.g., dementia, delirium, and Parkinson's disease), respiratory problems [e.g., asthma or chronic obstructive pulmonary disease (COPD)], gastrointestinal conditions [e.g., gastro-oesophageal reflux disease (GORD) or liver disease], and musculoskeletal disorders (e.g., osteoporosis or arthritis). The musculoskeletal cluster included at least one musculoskeletal disorder, with the most common being arthropathy, back/neck pain, and osteoporosis. Similar to the neuropsychiatric cluster, a variety of comorbidities, such as obesity, and cardiovascular and neurological diseases, were commonly found within this cluster. These insights into the complex interactions of multiple diseases in multimorbidity are yet to be translated into clinical use for patient benefit. However, alongside more longitudinal explorations of multimorbidity trajectories to decipher when individuals are at risk of developing their first and/or next disease [13], clustering might hold the key to developing timely and targeted drug therapies for patients displaying the early stages of a specific multimorbidity cluster.

Targeting the potential generic drivers of multimorbidity: core ageing processes

Given that advancing age is the primary non-modifiable risk factor for developing many chronic diseases alone or concomitantly, a new paradigm, the 'geroscience hypothesis', recently emerged for preventing, delaying, or even reversing age-related diseases and loss of function [14,15]. This concept is based on targeting the largely interconnected cellular and molecular mechanisms that underlie ageing, collectively termed the 'Hallmarks of Ageing' [16]. The strength of this hypothesis lies in the wealth of scientific understanding of the biology of ageing and the remarkable progress that has been made recently in preclinical and human studies to identify interventions that prevent and reduce the burden of chronic disease with advancing age [17]. Undoubtedly, such an approach also has the potential to revolutionise the way in which we develop new drugs for multimorbidity by targeting the generic drivers rather than focusing on single diseases within a cluster.

The ageing process underpins the progressive loss of function, homeostasis, and resilience in multiple organ systems with time and, once a particular threshold of impairment is reached, leads to the development and accumulation of clinically discernible diseases and/or frailty [18]. Although most older adults with frailty also have multimorbidity, many people with multimorbidity are not phenotypically frail; that is, those at high risk of adverse outcomes, such as falls, disability, hospitalisation, and death, because of a loss of physiological reserve [18]. Despite being separate concepts, there is large overlap between frailty and multimorbidity, and frailty can usefully be considered as a tool to identify older people with multimorbidity who are particularly vulnerable to dramatic changes in their physical and mental wellbeing. Established models of frailty, such as the 'Phenotype' model developed by Fried [19] and the Rockwood 'Cumulative Deficit' model [20], often include aspects of function, such as mobility impairment or difficulty with daily living activities, which are commonly missing from multimorbidity models. Functional improvements form a core component of many evidence-

based interventions to improve outcomes in frail individuals, and so measures of frailty can have an important role in geroscience-guided clinical trials targeting multimorbidity. The exact timing of multimorbidity onset is dependent on a multitude of genetic and environmental factors including, but not limited to, gender, ethnicity, obesity, lower socioeconomic status, and education level [8–10]. Delaying the progression to multimorbidity from the first onset of disease is one possible approach to clinical trial design to test the geroscience hypothesis that is being piloted in the Targeting Aging with Metformin (TAME) trial (discussed in more detail later) [21]. Thus, the ageing hallmarks could represent novel therapeutic targets in age-related diseases that commonly cluster together in individuals with multimorbidity.

Hallmarks of ageing: potential targets for drug interventions in multimorbidity

It is now widely recognised that nine interdependent cellular and molecular mechanisms underpin the ageing process (the 'Hallmarks of Ageing') [16]. This biogerontological understanding of ageing has determined that the initiating process is the accumulation of damage to DNA and proteins, epigenetic alterations, and reduced genome stability. This results in cellular responses that produce the aged phenotype, including reduced nutrient sensing, altered cell communication, reduced stem cell turnover, mitochondrial dysfunction, reduced proteostasis, and, ultimately, cell senescence [16].

The integrity and stability of the genome is continuously challenged by exogenous agents [e.g., ultraviolet (UV) radiation and chemicals] as well as endogenous threats [e.g., replication-induced DNA errors and telomere shortening, spontaneous hydrolytic reactions, and reactive oxygen species (ROS)] [22]. Although organisms have developed DNA repair mechanisms to minimise these lesions [e.g., DNA damage responses (DDRs)] and maintain the length and functionality of chromosomes (e.g., telomeres), excessive DNA damage and insufficient DNA repair inevitably result in genomic instability with chronological age [22]. Epigenetic alterations, such as DNA methylation, histone modifications (e.g., methylation and acetylation), and chromatin remodelling, also take place constantly throughout the lifespan of an organism to control gene transcription in response to environmental stimuli. Progressive deregulation of the 'the writers, readers, and erasers' of epigenetic marks [e.g., DNA methyltransferases, histone acetyltransferases, methyl CpG binding proteins (MBPs), and histone demethylases] with age leads to epigenetic drift, which is characterised by a loss of the normal balance of regulatory landmarks within the epigenome [23,24]. The best example of this is in DNA methylation, where ageing causes a bidirectional shift in methylation patterns, resulting in global hypomethylation across the genome [25], as well as hypermethylation at key regions of genes (e.g., CpG islands) [26], which can eventually lead to chromatin compaction and gene silencing. Overall, these epigenetic alterations contribute to the attenuated responsiveness to internal and external signals, the loss of phenotypic plasticity, and reduced regenerative capacity of stem cells, as well as the rise of hyperproliferative somatic cells that promote cancer development [24]. These changes can also permit the reactivation of transposable elements (TEs), such as the retrotransposon LINE1, which commonly compromise genomic integrity [27].

Another mechanism that results in the accumulation of damage and initiation of the ageing process is the loss of proteostasis. The two main proteolytic systems involved in maintaining protein quality control, namely the ubiquitin-proteasome and the autophagy-lysosomal system, both become impaired with age [28]. Bulk lysosomal degradation, known as autophagy, is responsible for clearing long-lived proteins and damaged organelles, and is under tight control from multiple transduction pathways based on environmental signals [29].

An important regulator of autophagy is the mammalian target of rapamycin (mTOR) and, in its two multiprotein complexes mTORC1 and mTORC2, it forms part of an interconnected network of nutrient-sensing systems that affect a variety of cellular processes [29]. Whereas mTOR senses high amino acid concentrations and regulates almost all aspects of anabolic metabolism, the insulin-IGF-1 signalling (IIS) pathway responds to changing levels of glucose/insulin, as well as growth hormone (albeit indirectly via IGF-1) [29]. Thus far, multiple lines of evidence from longevity studies in animals [30] have suggested that strong anabolic and trophic signals, via mTOR and IIS, are major contributors to accelerated ageing, and the effects of dietary restriction (DR) on increasing lifespan in model organisms are likely mediated via modulation of these interconnected pathways. Other pertinent nutrient-sensing systems implicated in the ageing process involve AMPK and sirtuins, which detect changes in AMP and NAD⁺ levels, respectively, to sense low energy states [29]. These nutrient sensors act in opposition to mTOR and IIS to signal nutrient scarcity and induce catabolic responses, and are accordingly upregulated with age [29].

Mitochondrial function is also perturbed with age as a result of mitochondrial DNA mutations, reduced mitochondriogenesis, destabilisation of the ATP-generating electron transport chain, and poorer quality control of damaged mitochondria by autophagy (known as mitophagy) [31]. Whereas mild mitochondrial dysfunction generates stress signals (e.g., ROS and low ATP production) that induce survival signals and trigger compensatory improvements in cellular fitness, in a process termed mitohormesis [32], with time these changes surpass a threshold that means oxidative stress becomes pathogenic [33].

Cellular senescence is a state of irreversible cell-cycle arrest, which can be induced by telomere shortening, DDRs, and mitochondrial stress [34]. Although senescent cells do not divide, they are metabolically active and secrete a variety of extracellular mediators, such as matrix metalloproteinases (MMPs), growth factors (vascular endothelial growth factor; VEGF), proinflammatory cytokines [e.g., interleukin-1 alpha (IL-1 α) and IL-6], and chemokines (IL-8), collectively referred to as the senescence-associated secretory phenotype (SASP) [35]. The SASP has an important physiological role by recruiting immune cells to clear apoptotic cell debris for wound healing (e.g., by macrophages) and senescent cells themselves (e.g., by natural killer cells) [36]. However, with ageing, there is an accumulation of senescent cells, in part because of reduced immune-mediated elimination [37], thus causing aberrant tissue function and repair [34].

The SASP also contributes to the chronic, low-grade inflammation, termed ‘inflammageing’, which is a primary example of altered cell communication as a hallmark of ageing [38]. Inflammageing is characterised by reduced levels of anti-inflammatory

cytokines, such as IL-10, and increased proinflammatory cytokines, such as IL-6 and IL-8, in the blood of older individuals [38]. Other potential contributors to inflammageing include impairment of the immune system with age (immunosenescence), increased adiposity, reduced physical activity, and leakage of microbial components from mucosal cavities into the blood because of reduced mucosal barrier integrity [39]. Importantly, the degree of inflammageing is associated with an increased risk of a range of chronic conditions, including cardiovascular disease, sarcopenia, osteoporosis, and dementia [40], and, thus, is a key potential driver of multimorbidity.

These highly interconnected core ageing processes not only provide a potential route to understanding the complex process of ageing and age-related diseases, but also offer an exciting opportunity to treat the generic drivers of multimorbidity to extend human healthspan.

Experimental evidence for targeting hallmarks of ageing in age-related disease and multimorbidity

Cellular senescence

Reducing the burden of senescent cells within tissues is one potential method of exploiting an ageing hallmark in the context of individual age-related diseases or multimorbidity, and has recently shown promise as a geroscience-informed therapeutic approach in a range of age-related diseases. Seminal papers in 2011 and 2016 showed that transgenic mice that selectively deleted senescent cells as they arose during midlife and old age had delayed tumorigenesis and age-related deterioration of several organs, including the heart, kidneys, eyes, skeletal muscle, and fat tissue [41,42]. Several existing drugs are able to induce apoptosis in senescent cells, so-called ‘senolytics’, including dasatinib (ephrin receptor inhibitor), quercetin (PI3 kinase pathway inhibitor), and navitoclax (Bcl-2/Bcl-xL anti-apoptotic protein inhibitor) [43–45]. Such compounds have now been tested in several pre-clinical disease models, showing improvements in cardiac [46] and vascular function [47], atherosclerosis [48], osteoporosis [46], osteoarthritis [49], and cognitive decline in tau-dependent neurodegenerative disease [50], while also attenuating frailty and prolonging overall healthspan and lifespan [51]. Encouragingly, the first human trials of senolytics, a combination of dasatinib and quercetin, have reported promising early results, which are discussed in more detail later [52,53]. Screening of compound libraries has also led to the discovery of novel senolytics, including selective Bcl-xL inhibitors [54], fisetin [54,55], heat-shock protein 90 (HSP90) inhibitors [56], and cardiac glycosides [57,58].

In an alternative approach, senostatic drugs, which target the secretory activity of senescent cells and in doing so reduce inflammageing, have also been tested. Selective inhibition of the JAK1/2 pathway was shown to have senostatic activity, reducing systemic inflammation, improving metabolic function and fat tissue homeostasis, and enhancing physical capacity in old, frail mice [59]. Small-molecule p38 inhibitors have also been effective in reversing T cell senescence and boosting vaccine efficacy in mice [60], and reducing inflammation and boosting cutaneous immunity to viral challenge in older humans [61].

Despite the evidence from animal models that the removal of senescent cells can have a positive impact upon ageing in several organ systems and disease states, senolytics need to be tested

TABLE 1
Geroscience-guided clinical trials of drugs targeting hallmarks of ageing^{a,b}

Drug	Target hallmark	Patient cohort	Duration	Dose	Outcome measures	NCT no.
Metformin	Nutrient sensing	N = 16; 60 years +; glucose intolerant	6 weeks	1700 mg daily versus placebo	Transcriptome changes in muscle and adipose tissue; insulin sensitivity and secretion	NCT02432287
		N = 109; 65 years +; SPPB score 3–12	16 weeks	1700 mg daily + RET versus placebo + RET	Type II myofibre CSA; normal density muscle size; muscle strength and total lean body mass insulin sensitivity	NCT02308228
	Autophagy	N = 25; 30–70 years; prediabetic; BMI 27–40	12 weeks	500 mg twice daily titrated to 1500 mg over 1 month versus placebo	body mass insulin sensitivity LC3 as marker of autophagy	NCT03309007
	Nutrient sensing	N = 120; 65 years +; prediabetic	Up to 3 years	850 mg once daily titrated to 850 mg twice daily versus placebo	Total lean body mass; 400 m walk speed test; muscle histology and transcriptomics	NCT01804049
	Inflammageing and senescence	N = 12; 60 years +; prediabetic; stable CAD; frail (SPPB score <9)	1 year	Up to 2 mg, given as 500 mg every 6–8 hr versus placebo	Frailty based on SPPB score; balance, gait speed, standing from chair; serum IL-6, MMPs, MCP-1, activin and plasminogen activator inhibitor as senescent markers	NCT03451006
		Immunosenescence	N = 50; 63–89 years	12 weeks	Up to 500 mg thrice daily versus placebo	Antibody response to PCV13; immune cell subset phenotyping
	NCT03713801 Nutrient sensing	N = 120; 60–90 years; prediabetic N = 150; 60 years +; prefrail	2 years	Up to 1000 mg twice daily versus placebo	Fried composite frailty score	NCT02570672
			16–24 weeks	500 mg thrice daily versus placebo	Frailty index (40 items); health-related quality-of-life questionnaire; gait speed, handgrip strength, and serum myostatin levels	NCT02325245
	Nutrient sensing and mitochondrial dysfunction	N = 148; 40–75 years; healthy N = 30; 60 years +; healthy	12 weeks	1500 mg daily versus placebo	Insulin sensitivity; mitochondrial function (complex I activity in ETC); blood glucose, insulin, and HbA1c levels	NCT04264897
			19 days	1 g twice daily for 2 weeks before 5 days of bed rest versus placebo	Change in muscle size by MRI	NCT03107884
Sirolimus (rapamycin), metformin and/or diclofenac (topical)	Nutrient sensing; inflammageing	N = 10; 55 years+; female only; healthy	4 weeks	Combined topical formulation of all three drugs versus metformin and diclofenac combination	Gene transcript changes; Wrinkle score	NCT03072485
Rapamycin	Nutrient sensing	N = 144; 18–85 years; healthy	8 hours	Single 16 mg dose (Rap) + AA supplement, HIRET + Rap, HIRET + AA, or Rap + AA + HIRET	Muscle protein synthesis; phosphorylation status of mTOR signalling proteins	NCT00891696

TABLE 1 (Continued)

Drug	Target hallmark	Patient cohort	Duration	Dose	Outcome measures	NCT no.
Dasatinib + quercetin	Senescence	N = 16; 40–80 years; DKD	2 weeks	100 mg dasatinib +1000 mg quercetin daily for 3 consecutive days; versus no intervention group	Senescent cell burden in skin, fat and blood; mesenchymal stem cell function; frailty index; kidney function	NCT02848131
		N = 5; 65 years +; early AD	12 weeks	2 days on/2 weeks off dasatinib + quercetin (six cycles)		NCT04063124
		N = 26; 50 years +; IPF; Male	3 weeks	100 mg dasatinib and 1250 mg quercetin daily 3 days/week over 3 weeks versus placebo		NCT02874989
Quercetin	Senescence	N = 106; healthy; 18–75 years	6 months	500 mg daily versus placebo	HIF-1, VEGF, EPO, and eNOS levels in blood; cerebrovascular blood flow; cognitive function	NCT01376011
Quercetin + 10 nutritional supplements	Senescence	N = 56; healthy; 40–60 years	6 months	650 mg quercetin + curcumin, fish oil, resveratrol, sesamin, acetyl-L-carnitine, lipoic acid, green and black teas, pomegranate extract and cinnamon bark versus multivitamin/mineral control group	Arterial stiffness by carotid-femoral pulse wave velocity; endothelial function; inflammation/oxidative stress markers; cardiometabolic risk factors	N/A
Fisetin	Senescence; inflammaging	N = 40; 70 years +; female only	2 months	20 mg/kg daily for 2 consecutive days for 2 months versus placebo	Gait speed	NCT03430037
		N = 40; 70 years +	N/A	20 mg/kg daily for 2 consecutive days only versus placebo	Blood inflammatory markers	NCT03675724
		N = 30; 40–80 years; CKD or DKD	12 months	20 mg/kg daily for 2 consecutive days only versus placebo	Inflammatory markers (e.g., CRP); mesenchymal stem cell function (e.g., migration); Fried composite frailty score; kidney function	NCT03325322
		N = 72; 40–80 years; OA	18 months	20 mg/kg daily for 2 consecutive days, followed by 28 days off, then 2 more consecutive days versus placebo	Systemic inflammatory markers; cartilage degeneration markers; MRI of knee articular cartilage; physical function (e.g., timed up and go, chair test); patient-reported outcomes of knee function and pain; time to start of alternative treatment	NCT04210986
NR or coenzyme Q10 supplement	Mitochondrial function; nutrient sensing	N = 30; 30–79 years; CKD	6 weeks	500 mg coenzyme Q10 twice daily, or; 600 mg NR twice daily versus placebo	Maximal aerobic capacity; PBMC mitochondrial energetics; oxidative stress and inflammatory markers; metabolomics; physical function and fatigue questionnaire	NCT03579693
MitoQ supplement (coenzyme Q10 derivative)	Mitochondrial function; nutrient sensing	N = 55; 60–79 years; healthy	6 weeks	20 mg daily MitoQ versus placebo	Oxidative stress (systemic oxidized LDL levels and nitrotyrosine in endothelial cells); cognitive function; arterial stiffness; motor function	NCT02597023

^a Given the wealth of preclinical evidence from animal models that ageing hallmarks can be targeted to delay and/or improve age-related diseases and frailty, human clinical trials are underway to investigate drugs known to target these core ageing processes. The use of diverse outcome measures that include biomarkers of ageing as well as more disease-specific measures will be vital to provide best possible evidence of efficacy for drug interventions.

^b Abbreviations: AA, amino acid; AAV-hTERT, adenovirus-associated human telomerase reverse transcriptase; AD, Alzheimer's disease; BMI, body mass index; CAD, coronary artery disease; CFS, clinical frailty score; CKD, chronic kidney disease; CRP, C-reactive protein; CSA, cross-sectional area; CSF, cerebrospinal fluid; DKD, diabetic kidney disease; eNOS, endothelial nitric oxide synthase; EPO, erythropoietin; ETC, electron transport chain; HbA_{1c}, glycated haemoglobin; HIF-1, hypoxia inducible factor; HIRET, high-intensity resistance exercise training; IL-6, interleukin-6; IPF, Idiopathic pulmonary fibrosis; LC3, microtubule-associated protein 1A/1B-light chain 3; LDL, low-density lipoprotein; MCP-1, monocyte chemoattractant protein-1; MMPs, matrix metalloproteinases; MRI, magnetic resonance imaging; NR, nicotinamide riboside; OA, osteoarthritis; PBMC, peripheral blood mononuclear cells; PCV13, pneumococcal conjugate vaccine; RET, resistance exercise training; SPPB, short physical performance battery; VEGF, vascular endothelial growth factor.

stringently in humans to validate these preclinical findings and minimise potential translational risks. Accordingly, there are several clinical trials underway using senolytics in age-related disease/frailty cohorts (Table 1) to evaluate the safety, feasibility, and efficacy of such interventions.

Mitochondrial dysfunction

Targeting the ageing hallmark of mitochondrial dysfunction has shown potential in several age-related pathologies. NAD levels decline with age and, although direct supplementation of NAD itself has had little success, NAD precursors, such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), have been more successful in increasing NAD tissue bioavailability [62]. For example, long-term NMN administration mitigates physiological decline in mice during normal ageing, with improvements in insulin sensitivity, plasma lipid profile, and eye and bone function, while simultaneously enhancing mitochondrial oxidative metabolism and attenuating age-associated mitonuclear protein imbalance in skeletal muscle [63]. In the context of obesity, NR supplementation protects against high-fat diet-induced metabolic abnormalities and defective mitochondrial function via the activation of SIRT1 and SIRT3 [64].

To date, the efficacy of NAD restoration in humans is less clear. Short-term NR supplementation has been shown to be well tolerated in middle-aged and older adults, leading to effective stimulation of NAD metabolism, as well as improvements in cardiovascular health [65] and decreased levels of circulating proinflammatory cytokines [66]. However, another clinical trial reported that NR supplementation in middle-aged, obese men with insulin resistance had no effect on NAD levels, respiratory capacity of skeletal muscle mitochondria, mitochondrial protein abundance, and mitochondrial fractional area [67]. Clinical trials using NR or Coenzyme Q10 derivatives are ongoing and will be vital in understanding the best possible way to target mitochondrial dysfunction and how this might impact other interconnected ageing hallmarks (Table 1).

Mitophagy and autophagy inducers

Urolithin A (UA), which is a natural dietary microflora-derived metabolite, specifically activates mitophagy and improved muscle health in animal models of ageing [68]. In a recent first-in-human clinical trial, synthetic UA supplementation had a good safety profile in old individuals and induced skeletal muscle gene expression changes indicative of improved mitochondrial function [69]. Spermidine, another inducer of mitophagy and autophagic flux in general, has also been tested as a dietary supplement in several preclinical animal models. So far, it has been shown to reduce hyperlipidaemia-induced atherosclerosis [70], protect against physiological cardiac ageing and heart failure [71], and reverse B cell senescence [72]. Spermidine-based nutritional interventions have now entered into a Phase IIb human clinical trial (SmartAge trial: NCT03094546) to investigate their effect on memory performance in older individuals with subjective cognitive decline and potential neurophysiological mechanisms of action [73].

Nutrient-sensing modulators

In addition to autophagy, other upstream components of the nutrient-sensing pathways can be manipulated to affect the ageing

process. Although originally approved for its immunosuppressive effects in acute renal allograft rejection, rapamycin (sirolimus), which inhibits the mTOR complex that is central to nutrient and growth factor-sensing pathways, is arguably the most well-established therapeutic approach based on geroscience to date [74]. Although only mTORC1 is directly inhibited by rapamycin, chronic exposure inhibits mTORC2 assembly and is thought to be responsible for the adverse effects associated with long-term rapamycin use [75].

Although rapamycin is still being tested in clinical trials (Table 1), more specific mTORC1 inhibitors will be key in overcoming this problem and novel rapamycin analogues (also termed 'rapalogs') have already been shown to have high selectivity [76]. Thus far, acute treatment with rapamycin (or rapamycin analogues) to inhibit mTORC1 in animal models has been effective in delaying, or even reversing, almost every age-related disease or decline in function, including cancer, cardiovascular disease, kidney disease, obesity, neurodegenerative diseases, sarcopenia, and immune senescence [77]. To date, only four human studies have investigated mTORC1 inhibition in the context of ageing, mainly immune system decline. The first study reported that weekly treatment with the rapamycin analogue RAD001 (everolimus) for 6 weeks in healthy old individuals was shown to be relatively well tolerated and improved the immune response to influenza vaccination [78]. Similarly, 6-week low-dose combination treatment with RAD001 alongside the catalytic site mTOR inhibitor BEZ235 was safe and led to decreased infection rates over a 12-month period in old subjects owing, at least in part, to an improved response to influenza vaccination [79]. Although 8-week treatment with rapamycin at a higher dose of 1 mg per day was shown to be safe in healthy older individuals, no beneficial effects on cognitive and physical performance, or clinical laboratory and self-perceived health status, were observed [80]. Most recently, topical low-dose application of rapamycin to the skin in a group of over 40-year olds was shown to increase collagen VII levels and reduce senescent cell-associated p16-INK4A expression within the skin [81].

Metformin, which is approved for treatment of T2DM, targets several ageing hallmarks because it leads to decreased insulin levels, decreased IGF-1 signalling, inhibition of mTOR, inhibition of mitochondrial complex I in the electron transport chain, reduced endogenous ROS production, and activation of AMPK [82]. Metformin also favourably affects metabolic and cellular processes that contribute to inflammation, autophagy, and cellular senescence, although it is unclear whether it affects all these pathways directly, or whether the observed effects are downstream of its single action on one mechanism of ageing [82]. Beyond these cellular processes, there is growing evidence from preclinical studies that metformin can delay ageing and prolong lifespan and healthspan. In mice, for example, metformin increased lifespan by 4–6% and improved multiple healthspan indices, such as physical performance and insulin sensitivity. As expected, these improvements were accompanied by increased AMPK activity, decreased chronic inflammation, and reduced oxidative damage [83]. However, these preclinical findings must be interpreted with some caution for several reasons. First, although mice are genetically tractable and allow testing of how candidate drugs impact evolutionarily conserved mechanisms of ageing, they are by no

means ideal as models of human ageing given the significant difference in lifespan compared with humans. Second, the lifespan-extending effects of metformin have not been replicated by the National Institute on Aging Interventions Testing Program, which tests the effects of drugs on longevity in three different locations using genetically heterogeneous mice. This might reflect the original effect being seen in only in male inbred mice, which are susceptible to obesity [84]. Third, high-dose metformin (1% w/w in diet) shortened the average lifespan in mice [83] and, thus, it will be important to identify safe dosing regimens in humans when determining the translational potential of metformin.

In humans, metformin has been shown to be effective in preventing T2DM in at-risk (obese or glucose-impaired) middle- and old-aged adults, while concomitantly improving cardiovascular disease risk factors and subclinical atherosclerosis [85]. In a pilot study in over 60-year olds with impaired glucose tolerance, 6 weeks of metformin use significantly altered metabolic and non-metabolic genes in both muscle and adipose tissue. Interestingly, these tissue-specific changes were predicted to be a result of metformin influencing upstream transcriptional regulators, such as mTORC1, as well as key ageing pathways linked to DNA repair, mitochondrial fatty acid oxidation, and inflammation [86]. Furthermore, metformin use has been associated with decreased cancer incidence, reduced cognitive impairment, lower rates of neurodegenerative diseases in older patients with T2DM, and reduced overall mortality in patients with T2DM as well as nondiabetics [82]. In contrast to these positive indications, metformin exposure in older patients with T2DM was associated with an increased risk of Alzheimer's disease, vascular dementia, and Parkinson's disease, and these observations were linked to increased dosage and duration of use [87]. A link between metformin use, increased risk of vitamin B₁₂ and vitamin B₆ deficiency, and cognitive dysfunction in older adults has also been reported [88]. Findings from recent clinical trials examining the effects of metformin alongside aerobic and/or resistance exercise training (AET/RET) in older adults were again contrary to expectation [89,90]. Metformin attenuated the improvement in insulin sensitivity and cardiorespiratory fitness after AET by inhibiting mitochondrial respiration in skeletal muscle [89], while preliminary results from the MASTERS trial (NCT02308228) found that long-term metformin use blunted the hypertrophic response to exercise and could not boost numbers of muscle-resident M2 (anti-inflammatory) macrophages after RET [90].

Such conflicting findings regarding metformin use in humans warrant future large-scale clinical trials. Currently, there are 11 clinical trials in the USA using metformin in patients with age-related conditions or frailty, aiming to reduce disease indicators or improve physical function respectively (Table 1). These trials will also be vital in discerning whether metformin can impact the root causes of ageing, beyond its known beneficial effects on metabolism. Monitoring effects on several hallmarks of ageing in these trials will have an important role in addressing this question.

Biomarkers of ageing for geroscience-guided clinical trials of multimorbidity

Any progress in preventing multimorbidity and late-life poor health will inevitably come from better predictors of their occurrence and the ability to intervene and monitor therapeutic

responses in individuals at greatest risk of developing multimorbidity. The use of surrogate biological measures, biomarkers, to detect individual variability in the progress of ageing as a risk indicator (i.e., accelerated ageing) and to monitor responses to interventions will be vital in testing the geroscience hypothesis. According to the American Federation for Aging Research (AFAR), these biomarkers should ideally: (i) predict the rate of ageing (i.e., mark exactly where an individual is in their lifespan) and mortality independent of chronological age; (ii) monitor a fundamental ageing process and not the effects of disease; and (iii) allow for practical (i.e., via blood test or imaging) longitudinal tracking in laboratory animals and humans [91]. Although there is no broad consensus on biomarkers of ageing for use in clinical trials, an expert panel convened in 2017 proposed a list for use in geroscience-informed trials, which included markers for: inflammation [C-reactive protein (CRP) and IL-6]; mitochondrial stress (GDF15); nutrient signalling (IGF-1 and fasting insulin); kidney function (cytostatin C); cardiovascular health (NT-proBNP); and metabolic ageing (glycated HbA1c) [21].

Several biomarkers of physiological state, including standardised measures of physical and mental capacity (e.g., cardiovascular and lung function, locomotion, strength, balance, and cognition) and systemic regulation of metabolism and immunity (e.g., insulin, IL-6, and CRP) have also been proposed for use in such trials [91]. Composite indices, such as the 'Biological Age' and 'Pace of Aging' scores, comprising many of these single biomarkers, can identify early-/middle-aged individuals at higher risk of impending multimorbidity because of accelerated ageing [92]. Other algorithmic measures of physiological vulnerability include the well-characterised 'frailty phenotype' [19], which is commonly used in the clinic, as well as the more recently developed frailty index (FI)-LAB [93], which uses commonly employed laboratory tests to generate a composite index of frailty. Such outcome measures might be more appropriate to monitor the effectiveness of interventions in older patients with established multimorbidity.

Recently, other indicators of biological age based on the epigenome [94], metabolome [95], and transcriptome [96] have been developed. For example, the 'Horvath epigenetic clock' is a multi-tissue DNA methylation-based predictor of chronological age based on the cumulative effect of the epigenetic maintenance system [94]. Deviation from the predicted chronological age of a subject using this tool is suggested as an indicator of their true biological age. This tool might have particular use in multimorbidity because it can elucidate tissue-specific accelerated ageing resulting from different diseases, and might enable us to identify which multimorbidity clusters should be targeted therapeutically. To date, these tools have not been extensively tested in clinical trials of drugs targeting ageing processes, but encouragingly they are starting to be adopted in some more recent geroscience-guided clinical trials, which are discussed in more detail in the following section.

Exemplars of geroscience-guided clinical trials

The exclusion of patients with multimorbidity from clinical trials is common, and often based on the proposition that the presence of comorbidities might dilute any potential benefits for the primary condition, or exacerbate any adverse effects of the treatment under investigation. The assessment of ongoing randomised controlled

trials (RCTs) for patients with ten common chronic conditions registered between 2014 and 2015 in the UK found that 79% of these RCTs excluded patients with a chronic comorbidity, while only 12% of RCTs were investigating interventions specifically for patients with more than two chronic conditions [97]. A study of more recent industry-sponsored clinical trials of novel drug therapies for chronic conditions found that the mean comorbidity count for trial participants in the UK was approximately half that seen in community-based patients, with no comorbidities being found to be particularly well represented across any of the trials [98]. It is vital that any large-scale geroscience-guided clinical trials are designed to include individuals across the multimorbidity spectrum, including at-risk individuals, patients with a single disease, and patients with established multimorbidity, to determine how interventions can stop or slow progression from single disease to multimorbidity. Outcome measures should also reflect this transition by measuring time to next disease diagnosis or new disease incidence in a particular timeframe, and although expensive, will require multiple follow-ups to track longitudinal changes over months and potentially years. Despite the paucity of clinical trials that specifically target multimorbid patients, here we highlight exemplars of geroscience-guided clinical trials that have begun to pave the way for improved drug discovery in the prevention and treatment of multimorbidity.

The first of these is the Thymus Regeneration, Immunorestitution, and Insulin Mitigation (TRIIM) trial, which was designed to investigate whether a combination therapy of recombinant growth hormone (rGH), dehydroepiandrosterone (DHEA), and metformin could prevent or reverse immunosenescence as an aspect of human ageing in healthy 51- to 65-year-old men [99]. The choice of drug formulation was based on prior evidence that growth hormone has thymotrophic and immune-reconstituting effects in animals [100] and patients with HIV [101], and that DHEA and metformin would be important to limit the diabetogenic properties of rGH administration. In addition, both DHEA [102] and metformin [82,84] have been shown to target aspects of the ageing process. This multidrug intervention for 12 months did restore thymic functional mass, and led to systemic increases in the lymphocyte:monocyte ratio, naïve CD4 and CD8 T cell pool, and frequency of CD4 recent thymic emigrants, all of which provide evidence of immunosenescence reversal [99]. Further to this and arguably more interesting, participants exhibited a significant decrease in their biological age based on four epigenetic clock biomarkers [99]. Overall, there was an average reduction in biological age of 2.5 years after 12 months and 1.5 years even after 3 months of treatment cessation [99]. Furthermore, the rate of ageing regression was shown to accelerate in months 9–12 after trial onset using all four epigenetic clock biomarkers, suggesting that even more long-term benefits are achievable with continuation of this combination drug therapy [99]. The TRIIM trial is a primary example of a geroscience-guided clinical trial that aims to prevent primary disease development in middle-to-old aged individuals at risk of developing their first age-related disease. Although the primary outcome of this study was to target immunosenescence, it made use of epigenetic age as another biomarker of ageing to provide evidence that multidrug formulations warrant further investigation in large-scale clinical trials, given their ability to impact the ageing process and mitigate each other's potential adverse effects.

Although preventative management of multimorbidity might be the ideal end goal, there is also a need to prevent progression from single diseases to established multimorbidity, which greatly complicates a patient's clinical management. The TAME trial aims to obtain evidence for a new indication in the use of metformin as a drug to delay multiple age-related diseases, as well as provide a geroscience-guided platform for trial design to test next-generation drugs [21,103]. Uniquely, the TAME trial plans to test metformin in older subjects with impending multimorbidity because of an ongoing single chronic disease, such as obesity, metabolic syndrome, hypertension, or hyperlipidaemia, and, rather than study the impact on each condition in isolation, its primary outcome will be to measure the time to new diagnosis of a second specific age-related disease, including cardiovascular events, cancer, dementia, and death [21,103]. Secondary and tertiary outcomes of the trial will include the accumulation rate of other age-related chronic conditions, such as depression, osteoporosis, and osteoarthritis, and acute events, such as falls and pneumonia, as well as functional (e.g., gait speed) and quality-of-life measures (e.g., pain or sleep quality). This focus on the accumulation of age-related diseases and functional endpoints associated with frailty marks a paradigm shift in clinical trial design, moving away from the one drug/one disease model towards targeting ageing processes and monitoring multiple disease outcomes instead. In such trials focusing on endpoints, such as disease diagnosis or death, biomarkers will be vital to help show that the intervention in question is affecting the underlying biology of ageing before sufficient clinical evidence is apparent, which could take many years. As a result, as described earlier, an expert workgroup has identified a list of candidate blood-based biomarkers that could be applied in geroscience-guided clinical trials, such as TAME [21]. Such trial designs will be key to stimulating new pharmacological therapies to tackle the challenge of multimorbidity.

Finally, in individuals with well-established multimorbidity, newly discovered drugs would ideally be able to reverse chronic diseases and, if not, should at least be able to slow their progression so as to maintain or improve function and late-life quality of life. First-in-human clinical trials using the senolytic drugs dasatinib and quercetin (DQ) have now begun to test this possibility, with some promising preliminary results. One pilot study showed that short-term intermittent administration (three doses per week for 3 weeks) of DQ in patients with idiopathic pulmonary fibrosis (IPF), which is a cellular senescence-driven disease, was feasible and safe, and, more importantly, improved measures of physical function (e.g., 6-min walk distance, 4 m-gait speed, and chair-stand time) [52]. Although these measures of physical function were significantly and clinically meaningfully improved, other outcomes, including pulmonary function, circulating SASP factors, and FI-LAB, were not significantly different and only showed a trend towards improvement that might be attributable to the very small sample size in this pilot study [52]. Despite this, moderate correlations were seen between physical function improvement and these other biomarkers. For example, faster 4 m-gait speeds and chair-stand times were associated with decreased levels of different SASP factors, and improved FI-LAB with many proinflammatory cytokines [52]. Another pilot study in patients with diabetic kidney disease showed that just a 3-day DQ treatment reduced senescent cell burden in the skin and adipose tissue [53]. Accordingly,

circulating SASP factors, such as IL-1 α , IL-6, MMP-9, and MMP-12, and adipose tissue-resident macrophages were also reduced after DQ treatment [53]. Although much remains to be done to optimise systemic administration of senolytic drugs, they might hold huge potential in the treatment of multimorbidity, given the wide-ranging benefits of the systemic removal of senescent cells in many age-related diseases.

Novel ageing targets and future directions

The field of geroscience is moving fast with regards to repurposed drugs that were not originally designed to target a specific aspect of the ageing process per se (e.g., metformin, rapamycin, dasatinib, quercetin, and navitoclax). Therefore, developing drugs that specifically target core ageing processes has the potential to improve efficacy and reduce adverse effects for patients with multimorbidity, already at high risk of adverse effects because of polypharmacy. Examining the efficacy of different rapalogs [104], such as RAD001 and BEZ235, which have already been effective against immunosenescence in human trials [78,79], in the context of other age-related diseases is an important consideration because the impact upon mTORC signalling can vary greatly based on the different biochemical properties of the rapalogs. The discovery of natural mimetics of metformin and rapamycin with better safety profiles, by applying bioinformatics and deep learning methods to natural compound libraries, has already yielded some promising novel candidates [105].

Screening of chemical or natural compound libraries will facilitate the discovery of drugs that target some of the more novel molecules regulating the ageing hallmarks (Table 2). For example, transposable elements (TEs), which can move within the genome, build up, and contribute to genomic instability in the ageing process, are one such novel target [106]. The Piwi-piRNA pathway, which was originally discovered in the *Drosophila* male germline to repress the activity of TEs [107], is also active within human haematopoietic stem cells [108], and might represent a targetable

pathway to oppose TE-mediated genomic instability and stem cell exhaustion. Mesencephalic-astrocyte-derived neurotrophic factor (MANF) is a stress-response protein now shown to have immunomodulatory and systemic anti-inflammatory properties capable of improving age-related metabolic dysfunction and liver disease [109], and has potential for therapeutic application. Selective small-molecule inhibitors of the NLRP3 inflammasome to target inflammaging have also shown promise in preclinical studies [110,111]. Trial design when testing any candidate drugs against these ageing targets needs serious consideration. The inclusion of patients with multimorbidities in clinical trials will be important to test whether the benefit:risk ratio of any pharmacological intervention is sufficient in the context of expected disease progression and pre-existing adverse effects from polypharmacy. For some trial designs, this decision might be similar to that for chemotherapy in advanced cancers, whereas trials testing drugs for primary prevention might have to be more cautious. Different approaches, whereby one drug or drug type is tested using several primary outcomes in a 'basket trial' design, or several drugs targeting different ageing hallmarks are investigated in an 'umbrella trial' design, such as the TRIIM trial, will maximise the probability of clarifying which pharmacological approach works best for different multimorbidity clusters. Taking advantage of some of these novel drug targets (Table 2) might enable us to maximise the therapeutic impact by targeting multiple ageing hallmarks simultaneously, in the hope that an additive, synergistic effect would be of greater benefit to patients falling within a particular multimorbidity cluster. Targeting NLRC4, an important contributor to inflammaging [112,113], kalirin (KALRN), a multifunctional signalling protein implicated in atherosclerosis and neurodegeneration [114–117], and KLHL20, a master regulator of autophagy termination [118] would be just one example of doing this to indirectly impact many of the interconnected ageing hallmarks at once (Fig. 2). Thus far, combination therapies of more well-known candidate drugs have shown promising early results in their ability

TABLE 2

Potential novel drug targets based on ageing hallmarks for age-related diseases and multimorbidity^a

Novel target	Ageing Hallmark	Refs
Transposable elements/Piwi-piRNA pathway	Genomic instability; stem cell exhaustion; epigenetic alterations	[106–108]
MANF	Nutrient sensing; altered cell communication /inflammaging	[109]
NLRP3 inflammasome	Altered cell communication /inflammaging	[110–112]
NLRC4 inflammasome	Altered cell communication /inflammaging	[112,113]
Kalirin (KALRN)	Altered cell communication	[114–117]
KLHL20	Autophagy; nutrient sensing	[118]
V-ATPases	Autophagy	[121]
Rheb	Nutrient sensing; autophagy	[122]
SIRT1, SIRT3, SIRT6	Genomic instability; nutrient sensing; mitochondrial dysfunction; senescence	[123]
Parkin/PINK1	Autophagy; mitochondrial dysfunction; senescence	[124,125]
Alpha-klotho	Mitochondrial dysfunction; altered cell communication (i.e., inflammaging)	[126,127]
Cdc42	Senescence; stem cell exhaustion	[128,129]
cGAS/STING	Genomic instability; senescence; altered cell communication (i.e., inflammaging)	[130]
ROCK	Mitochondrial dysfunction; senescence; nutrient sensing; altered cell communication (i.e., Inflammaging)	[131–133]
Retrotransposable elements (e.g., LINE1)	Genomic instability; senescence; altered cell communication (i.e., inflammaging)	[134,135]
Sestrins	Senescence; nutrient sensing; autophagy	[59,136]
LRRK2	Mitochondrial dysfunction; autophagy	[137]
PARP1	Genomic instability; mitochondrial dysfunction	[138]

^aListed are recently discovered molecules or pathways that have been implicated in the ageing process and age-related diseases and warrant further investigation as drug targets to delay, prevent, or reverse components of multimorbidity.




FIGURE 2

Targeting multiple ageing hallmarks simultaneously using novel drug targets. Novel drug targets, such as kalirin (KALRN), KLHL20, and NLRC4, which fall at the nexus between multiple ageing hallmarks (e.g., altered cell metabolism/communication, inflammation, senescence, and DNA damage/repair) might be one method of maximising therapeutic impact for patients with multimorbidity in geroscience-guided clinical trials. Arrows represent how core ageing processes [e.g., oxidative stress, immune factors, senescence-associated secretory phenotype (SASP), DNA damage response (DDR), and telomere/replication stress] link different ageing hallmarks together.

to target core ageing processes in animal models [119,120] and humans [52,53,79,99].

Nonetheless, such multidimensional geroscience-guided clinical trials for multimorbidity will need substantial funding, given the necessity for long-term follow-ups to truly test the antiageing potential of candidate drugs. Although industry-based funding will have an important role in this, pharmaceutical companies might be less inclined to fund such geroscience-guided clinical trials because of their inherent risks and the fact that ageing is still not considered an indication for drug development by the US Food and Drug Administration (FDA) [21]; thus, government funding will be a necessity. The establishment of national networks, such as the National Institute on Ageing (NIA) R24 Geroscience Network, which comprises 18 ageing centres and academic groups across the USA, will facilitate accelerated progress in funding, drug development and human testing via the shared generation of standardised ‘toolkits’

for ageing-related outcomes and adverse events that are comparable across multiple trials, as well as a national geroscience biobank to facilitate widespread, invaluable access to biological samples generated from unique cohorts of frail and older individuals with multimorbidities enrolled in clinical trials [14].

Acknowledgements

C.E. and C.G. are funded by the UK SPINE Knowledge Exchange network. We thank Teresa O’Leary for her help in identifying geroscience-informed trials in the USA. This paper presents independent research supported by the NIHR Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social care.

References

- UN (2017) *World Population Prospects: The 2017 Revision*. UN Department of Economic and Social Affairs
- Crimmins, E.M. (2015) Lifespan and healthspan: past, present, and promise. *Gerontologist* 55, 901–911
- Salomon, J.A. *et al.* (2012) Healthy life expectancy for 187 countries, 1990–2010, a systematic analysis for the Global Burden Disease Study 2010. *Lancet* 380, 2144–2162
- Jagger, C. *et al.* (2008) Inequalities in healthy life years in the 25 countries of the European Union in 2005, a cross-national meta-regression analysis. *Lancet* 372 (9656), 2124–2131
- Academy of Medical Sciences (2018) *Multimorbidity: A Priority for Global Health Research: Full Report*. Academy of Medical Sciences
- Rijken, M. *et al.* (2013) ICARE4EU: improving care for people with multiple chronic conditions in Europe. *Eurohealth* 19, 29–31
- DuGoff, E.H. *et al.* (2014) Multiple chronic conditions and life expectancy: a life table analysis. *Med. Care* 52, 688–6894
- Fabbri, E. *et al.* (2015) Aging and multimorbidity: new tasks, priorities, and frontiers for integrated gerontological and clinical research. *J. Am. Med. Dir. Assoc.* 16, 640–647
- Figueira, I. *et al.* (2016) Interventions for age-related diseases: shifting the paradigm. *Mech. Ageing Dev.* 160, 69–92
- Barnett, K. *et al.* (2012) Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet* 380 (9836), 37–43
- Wastesson, J.W. *et al.* (2018) An update on the clinical consequences of polypharmacy in older adults: a narrative review. *Expert Opin. Drug Saf.* 17, 1185–1196
- Prados-Torres, A. *et al.* (2014) Multimorbidity patterns: a systematic review. *J. Clin. Epidemiol.* 67, 254–266
- Strauss, V.Y. *et al.* (2014) Distinct trajectories of multimorbidity in primary care were identified using latent class growth analysis. *J. Clin. Epidemiol.* 67, 1163–1171
- Justice, J. *et al.* (2016) Frameworks for proof-of-concept clinical trials of interventions that target fundamental aging processes. *J. Gerontol. A Biol. Sci. Med. Sci.* 71, 1415–1423
- Kennedy, B.K. (2014) Geroscience: linking aging to chronic disease. *Cell* 159, 709–713
- López-Otín, C. *et al.* (2013) The hallmarks of aging. *Cell* 153, 1194–1217
- Campisi, J. *et al.* (2019) From discoveries in ageing research to therapeutics for healthy ageing. *Nature* 571, 183–192

- 18 Clegg, A. *et al.* (2013) Frailty in elderly people. *Lancet* 381, 752–762
- 19 Fried, L.P. *et al.* (2001) Frailty in older adults: evidence for a phenotype. *J. Gerontol. A Biol. Sci. Med. Sci.* 56, M14–M56
- 20 Rockwood, K. *et al.* (2005) A global clinical measure of fitness and frailty in elderly people. *CMAJ* 173, 489–495
- 21 Justice, J.N. *et al.* (2018) A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup. *Geroscience* 40, 419–436
- 22 Hoeijmakers, J.H. (2009) DNA damage, aging, and cancer. *N. Engl. J. Med.* 361, 1475–1485
- 23 Talens, R.P. *et al.* (2012) Epigenetic variation during the adult lifespan: cross-sectional and longitudinal data on monozygotic twin pairs. *Aging Cell* 11, 694–703
- 24 Fraga, M.F. and Esteller, M. (2007) Epigenetics and aging: the targets and the marks. *Trends Genet.* 23, 413–418
- 25 McClay, J.L. *et al.* (2014) A methylome-wide study of aging using massively parallel sequencing of the methyl-CpG-enriched genomic fraction from blood in over 700 subjects. *Hum. Mol. Genet.* 23, 1175–1185
- 26 Hannum, G. *et al.* (2013) Genome-wide methylation profiles reveal quantitative views of human aging rates. *Mol. Cell.* 49, 359–367
- 27 Jönsson, M.E. *et al.* (2019) Activation of neuronal genes via LINE-1 elements upon global DNA demethylation in human neural progenitors. *Nat. Commun.* 10, 3182
- 28 Koga, H. *et al.* (2011) Protein homeostasis and aging: the importance of exquisite quality control. *Ageing Res. Rev.* 10, 205–215
- 29 Liu, G.Y. and Sabatini, D.M. (2020) Author Correction: mTOR at the nexus of nutrition, growth, ageing and disease. *Nat. Rev. Mol. Cell Biol.* 21, 246
- 30 Gems, D. and Partridge, L. (2013) Genetics of longevity in model organisms: debates and paradigm shifts. *Annu. Rev. Physiol.* 75, 621–644
- 31 Sun, N. *et al.* (2016) The mitochondrial basis of aging. *Mol. Cell.* 61, 654–666
- 32 Yun, J. and Finkel, T. (2014) Mitohormesis. *Cell Metab.* 19, 757–766
- 33 Hekimi, S. *et al.* (2011) Taking a ‘good’ look at free radicals in the aging process. *Trends Cell Biol.* 21, 569–576
- 34 Childs, B.G. *et al.* (2015) Cellular senescence in aging and age-related disease: from mechanisms to therapy. *Nat. Med.* 21, 1424–1435
- 35 Coppé, J.P. *et al.* (2010) The senescence-associated secretory phenotype: the dark side of tumor suppression. *Annu. Rev. Pathol.* 5, 99–118
- 36 Sagiv, A. and Krizhanovsky, V. (2013) Immunosurveillance of senescent cells: the bright side of the senescence program. *Biogerontology* 14, 617–628
- 37 Pereira, B.I. *et al.* (2019) Senescent cells evade immune clearance via HLA-E-mediated NK and CD8+ T cell inhibition. *Nat. Commun.* 10, 2387
- 38 Bartlett, D.B. *et al.* (2012) The age-related increase in low-grade systemic inflammation (inflammaging) is not driven by cytomegalovirus infection. *Aging Cell* 11, 912–915
- 39 Fulop, T. (2018) Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? *Front. Immunol.* 8, 1960
- 40 Ferrucci, L. and Fabbri, E. (2018) Inflammaging: chronic inflammation in ageing, cardiovascular disease, and frailty. *Nat. Rev. Cardiol.* 15, 505–522
- 41 Baker, D.J. *et al.* (2011) Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. *Nature* 479, 232–236
- 42 Baker, D.J. *et al.* (2016) Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. *Nature* 530, 184–189
- 43 Kirkland, J.L. and Tchkonja, T. (2017) Cellular senescence: a translational perspective. *EBioMedicine* 21, 21–28
- 44 Soto-Gamez, A. and Demaria, M. (2017) Therapeutic interventions for aging: the case of cellular senescence. *Drug Discov Today* 22, 786–795
- 45 van Deursen, J.M. (2019) Senolytic therapies for healthy longevity. *Science* 364, 636–637
- 46 Zhu, Y. *et al.* (2015) The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. *Aging Cell* 14, 644–658
- 47 Roos, C.M. *et al.* (2016) Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. *Aging Cell* 15, 973–977
- 48 Childs, B.G. *et al.* (2016) Senescent intimal foam cells are deleterious at all stages of atherosclerosis. *Science* 354, 472–477
- 49 Jeon, O.H. *et al.* (2017) Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. *Nat. Med.* 23, 775–781
- 50 Bussian, T.J. *et al.* (2018) Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. *Nature* 562, 578–582
- 51 Xu, M. *et al.* (2018) Senolytics improve physical function and increase lifespan in old age. *Nat. Med.* 24, 1246–1256
- 52 Justice, J.N. *et al.* (2019) Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. *EBioMedicine* 40, 554–563
- 53 Hickson, L.J. *et al.* (2019) Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease published correction appears in *EBioMedicine* (2020) 52, 102595. *EBioMedicine* 47, 446–456
- 54 Zhu, Y. *et al.* (2017) New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. *Aging (Albany NY)* 9, 955–963
- 55 Yousefzadeh, M.J. *et al.* (2018) Fisetin is a senotherapeutic that extends health and lifespan. *EBioMedicine* 36, 18–28
- 56 Fuhrmann-Stroissnigg, H. *et al.* (2017) Identification of HSP90 inhibitors as a novel class of senolytics. *Nat. Commun.* 8, 422
- 57 Triana-Martínez, F. *et al.* (2019) Identification and characterization of Cardiac Glycosides as senolytic compounds. *Nat. Commun.* 10, 4731
- 58 Guerrero, A. *et al.* (2019) Cardiac glycosides are broad-spectrum senolytics. *Nat. Metab.* 1, 1074–1088
- 59 Xu, M. *et al.* (2015) JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. *Proc. Natl. Acad. Sci. U. S. A.* 112, E6301–E6310
- 60 Lanna, A. *et al.* (2017) A sestrin-dependent Erk-Jnk-p38 MAPK activation complex inhibits immunity during aging. *Nat. Immunol.* 18, 354–363
- 61 Vukmanovic-Stejic, M. *et al.* (2018) Enhancement of cutaneous immunity during aging by blocking p38 mitogen-activated protein (MAP) kinase-induced inflammation. *J. Allergy Clin. Immunol.* 142, 844–856
- 62 Okabe, K. *et al.* (2019) Implications of altered NAD metabolism in metabolic disorders. *J. Biomed. Sci.* 26, 34
- 63 Mills, K.F. *et al.* (2016) Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. *Cell Metab.* 24, 795–806
- 64 Cantó, C. *et al.* (2012) The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. *Cell Metab.* 15, 838–847
- 65 Martens, C.R. *et al.* (2018) Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. *Nat. Commun.* 9, 1286
- 66 Elhassan, Y.S. *et al.* (2019) Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. *Cell Rep.* 28, 1717–1728
- 67 Dollerup, O.L. *et al.* (2020) Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men. *J. Physiol.* 598, 731–754
- 68 Ryu, D. *et al.* (2016) Urolithin A induces mitophagy and prolongs lifespan in *C. elegans* and increases muscle function in rodents. *Nat. Med.* 22, 879–888
- 69 Andreux, P.A. *et al.* (2019) The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. *Nat. Metab.* 1, 595–603
- 70 Tyrrell, D.J. *et al.* (2020) Age-associated mitochondrial dysfunction accelerates atherogenesis. *Circ. Res.* 126, 298–314
- 71 Eisenberg, T. *et al.* (2016) Cardioprotection and lifespan extension by the natural polyamine spermidine. *Nat. Med.* 22, 1428–1438
- 72 Zhang, H. *et al.* (2019) Polyamines control eIF5A hypusination, TFEB translation, and autophagy to reverse B cell senescence. *Mol. Cell* 76, 110–125
- 73 Wirth, M. *et al.* (2019) Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline (SmartAge)-study protocol for a randomized controlled trial. *Alzheimers Res. Ther.* 11, 36
- 74 Arriola Apelo, S.I. and Lamming, D.W. (2016) Rapamycin: an InhibiTOR of aging emerges from the soil of Easter Island. *J. Gerontol. A Biol. Sci. Med. Sci.* 71, 841–849
- 75 Lamming, D.W. *et al.* (2012) Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. *Science* 335, 1638–1643
- 76 Schreiber, K.H. *et al.* (2019) A novel rapamycin analog is highly selective for mTORC1 *in vivo*. *Nat. Commun.* 10, 3194
- 77 Kennedy, B.K. and Lamming, D.W. (2016) The mechanistic target of rapamycin: the grand conductor of metabolism and aging. *Cell Metab.* 23, 990–1003
- 78 Mannick, J.B. *et al.* (2014) mTOR inhibition improves immune function in the elderly. *Sci. Transl. Med.* 6, 268ra179
- 79 Mannick, J.B. *et al.* (2018) TORC1 inhibition enhances immune function and reduces infections in the elderly. *Sci. Transl. Med.* 10, eaaq1564
- 80 Kraig, E. *et al.* (2018) A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. *Exp. Gerontol.* 105, 53–69
- 81 Chung, C.L. *et al.* (2019) Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial. *Geroscience* 41, 861–869
- 82 Barzilai, N. *et al.* (2016) Metformin as a tool to target aging. *Cell Metab.* 23, 1060–1065
- 83 Martin-Montalvo, A. *et al.* (2013) Metformin improves healthspan and lifespan in mice. *Nat. Commun.* 4, 2192

- 84 Glossmann, H.H. and Lutz, O.M.D. (2019) Metformin and aging: a review. *Gerontology* 65, 581–590
- 85 Goldberg, R.B. *et al.* (2017) Effect of long-term metformin and lifestyle in the Diabetes Prevention Program (DPP) and its outcome study on coronary artery calcium. *Circulation* 136, 52–64
- 86 Kulkarni, A.S. *et al.* (2018) Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults. *Aging Cell* 17, e12723
- 87 Kuan, Y.C. *et al.* (2017) Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 79, 77–83
- 88 Porter, K.M. *et al.* (2019) Hyperglycaemia and metformin use are associated with B-vitamin deficiency and cognitive dysfunction in older adults. *J. Clin. Endocrinol. Metab.* 104, 4837–4847
- 89 Konopka, A.R. *et al.* (2019) Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. *Aging Cell* 18, e12880
- 90 Walton, R.G. *et al.* (2019) Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: a randomised, double blind, placebo-controlled, multicentre trial: the MASTERS trial. *Aging Cell* 18, e13039
- 91 Lara, J. *et al.* (2015) A proposed panel of biomarkers of healthy ageing. *BMC Med.* 13, 222
- 92 Belsky, D.W. *et al.* (2015) Quantification of biological aging in young adults. *Proc. Natl. Acad. Sci. U. S. A.* 112, E4104–E4110
- 93 Rockwood, K. *et al.* (2015) A frailty index based on common laboratory tests in comparison with a clinical frailty index for older adults in long-term care facilities. *J. Am. Med. Dir. Assoc.* 16, 842–847
- 94 Horvath, S. (2013) DNA methylation age of human tissues and cell types published correction appears in *Genome Biol.* (2015) 16, 96. *Genome Biol* 14, R115
- 95 Hertel, J. *et al.* (2016) Measuring biological age via metabolomics: the metabolic age score. *J. Proteome Res.* 15, 400–410
- 96 Peters, M.J. *et al.* (2015) The transcriptional landscape of age in human peripheral blood. *Nat. Commun.* 6, 8570
- 97 Buffel du Vaure, C. *et al.* (2016) Exclusion of patients with concomitant chronic conditions in ongoing randomised controlled trials targeting 10 common chronic conditions and registered at ClinicalTrials.gov: a systematic review of registration details. *BMJ Open* 6, e012265
- 98 Hanlon, P. *et al.* (2019) Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysis. *BMC Med* 17, 201
- 99 Fahy, G.M. *et al.* (2019) Reversal of epigenetic aging and immunosenescent trends in humans. *Aging Cell* 18, e13028
- 100 Kelley, K.W. *et al.* (1986) GH3 pituitary adenoma cells can reverse thymic aging in rats. *Proc. Natl. Acad. Sci. U. S. A.* 83, 5663–5667
- 101 Plana, M. *et al.* (2011) The reconstitution of the thymus in immunosuppressed individuals restores CD4-specific cellular and humoral immune responses. *Immunology* 133, 318–328
- 102 Forti, P. *et al.* (2012) Serum dehydroepiandrosterone sulfate and adverse health outcomes in older men and women. *Rejuvenation Res.* 15, 349–358
- 103 Justice, J.N. *et al.* (2018) Development of trials to extend healthy lifespan. *Cardiovasc. Endocrinol. Metab.* 7, 80–83
- 104 Walters, H.E. and Cox, L.S. (2018) mTORC inhibitors as broad-spectrum therapeutics for age-related diseases. *Int. J. Mol. Sci.* 19, 2325
- 105 Aliper, A. *et al.* (2017) Towards natural mimetics of metformin and rapamycin. *Aging (Albany NY)* 9, 2245–2268
- 106 Sturm, Á. *et al.* (2015) The mechanism of ageing: primary role of transposable elements in genome disintegration. *Cell. Mol. Life Sci.* 72, 1839–1847
- 107 Sturm, Á. *et al.* (2017) The Piwi-piRNA pathway: road to immortality. *Aging Cell* 16, 906–911
- 108 Sharma, A.K. *et al.* (2001) Human CD34(+) stem cells express the hiwi gene, a human homologue of the *Drosophila* gene piwi. *Blood* 97, 426–434
- 109 Sousa-Victor, P. *et al.* (2019) MANF regulates metabolic and immune homeostasis in ageing and protects against liver damage. *Nat. Metab.* 1, 276–290
- 110 van Hout, G.P. *et al.* (2017) The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. *Eur. Heart J.* 38, 828–836
- 111 Marín-Aguilar, F. *et al.* (2019) NLRP3 inflammasome inhibition by MCC950 in aged mice improves health via enhanced autophagy and PPAR α activity. *J. Gerontol. A Biol. Sci. Med. Sci.* . <http://dx.doi.org/10.1093/gerona/glz239> Published online October 11, 2019
- 112 Furman, D. *et al.* (2017) Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. *Nat. Med.* 23, 174–184
- 113 Mejias, N.H. *et al.* (2018) Contribution of the inflammasome to inflammaging. *J. Inflamm.* 15, 23
- 114 Wu, J.H. *et al.* (2013) Kalirin promotes neointimal hyperplasia by activating Rac in smooth muscle cells. *Arterioscler. Thromb. Vasc. Biol.* 33, 702–708
- 115 Wu, J. *et al.* (2017) The atherosclerosis candidate gene product kalirin reduces atherosclerosis via macrophage-specific mechanisms. *Circulation* 136, A16543
- 116 Cissé, M. *et al.* (2017) The transcription factor XBP1s restores hippocampal synaptic plasticity and memory by control of the Kalirin-7 pathway in Alzheimer model. *Mol. Psychiatry* 22, 1562–1575
- 117 Xie, Z. *et al.* (2019) Kalirin-7 prevents dendritic spine dysgenesis induced by amyloid beta-derived oligomers. *Eur. J. Neurosci.* 49, 1091–1101
- 118 Liu, C.C. *et al.* (2016) Cul3-KLHL20 ubiquitin ligase governs the turnover of ULK1 and VPS34 complexes to control autophagy termination. *Mol. Cell* 61, 84–97
- 119 Castillo-Quan, J.I. *et al.* (2019) A triple drug combination targeting components of the nutrient-sensing network maximizes longevity. *Proc. Natl. Acad. Sci. U. S. A.* 116, 20817–20819
- 120 Davidsohn, N. *et al.* (2019) A single combination gene therapy treats multiple age-related diseases published correction appears in *Proc. Natl. Acad. Sci. U. S. A.* (2020) 117, 790. *Proc. Natl. Acad. Sci. U. S. A.* 116, 23505–23511
- 121 Colacurcio, D.J. and Nixon, R.A. (2016) Disorders of lysosomal acidification—the emerging role of v-ATPase in aging and neurodegenerative disease. *Ageing Res. Rev.* 32, 75–88
- 122 Mahoney, S.J. *et al.* (2018) A small molecule inhibitor of Rheb selectively targets mTORC1 signaling. *Nat. Commun.* 9, 548
- 123 Grabowska, W. *et al.* (2017) Sirtuins, a promising target in slowing down the ageing process. *Biogerontology* 18, 447–476
- 124 Cornelissen, T. *et al.* (2018) Deficiency of parkin and PINK1 impairs age-dependent mitophagy in *Drosophila*. *Elife* 7, e35878
- 125 Sliter, D.A. *et al.* (2018) Parkin and PINK1 mitigate STING-induced inflammation. *Nature* 561, 258–262
- 126 Sahu, A. *et al.* (2018) Age-related declines in α -Klotho drive progenitor cell mitochondrial dysfunction and impaired muscle regeneration. *Nat. Commun.* 9, 4859
- 127 Kuro-o, M. (2019) The Klotho proteins in health and disease. *Nat. Rev. Nephrol.* 15, 27–44
- 128 Florian, M.C. *et al.* (2017) Expression and activity of the small RhoGTPase Cdc42 in blood cells of older adults are associated with age and cardiovascular disease. *J. Gerontol. A Biol. Sci. Med. Sci.* 72, 1196–1200
- 129 Chaker, D. *et al.* (2018) Inhibition of the RhoGTPase Cdc42 by ML141 enhances hepatocyte differentiation from human adipose-derived mesenchymal stem cells via the Wnt5a/PI3K/miR-122 pathway: impact of the age of the donor. *Stem Cell Res. Ther.* 9, 167
- 130 Lan, Y.Y. *et al.* (2019) Extranuclear DNA accumulates in aged cells and contributes to senescence and inflammation. *Aging Cell* 18, e12901
- 131 Kang, H.T. *et al.* (2017) Chemical screening identifies ROCK as a target for recovering mitochondrial function in Hutchinson-Gilford progeria syndrome. *Aging Cell* 16, 541–550
- 132 Park, J.T. *et al.* (2018) A crucial role of ROCK for alleviation of senescence-associated phenotype. *Exp. Gerontol.* 106, 8–15
- 133 Moskal, N. *et al.* (2020) ROCK inhibitors upregulate the neuroprotective Parkin-mediated mitophagy pathway. *Nat. Commun.* 11, 88
- 134 Simon, M. *et al.* (2019) LINE1 derepression in aged wild-type and SIRT6-deficient mice drives inflammation. *Cell Metab.* 29, 871–885
- 135 De Cecco, M. *et al.* (2019) L1 drives IFN in senescent cells and promotes age-associated inflammation. *Nature* 566, 73–78
- 136 Segalés, J. *et al.* (2020) Sestrin prevents atrophy of disused and aging muscles by integrating anabolic and catabolic signals. *Nat. Commun.* 11, 189
- 137 Bardai, F.H. *et al.* (2018) Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics. *PLoS Biol.* 16, e2006265
- 138 Zha, S. *et al.* (2018) PARP1 inhibitor (PJ34) improves the function of aging-induced endothelial progenitor cells by preserving intracellular NAD⁺ levels and increasing SIRT1 activity. *Stem Cell Res. Ther.* 9, 224